Contents

Search

danazol (Danocrine)

Tradename: Danocrine. Indications: 1) endometriosis 2) fibrocystic breast disease 3) hereditary angioedema 4) precocious puberty [4] 5) gynecomastia 6) menorrhagia [4] Dosage: 1) endometriosis: start 400 mg PO BID, then titrate downward 2) fibrocystic breast disease: 50-300 mg PO BID 3) hereditary angioedema: 400-600 mg/day divided BID-TID Tabs: 50, 100, 200 mg. Adverse effects: (generally reversible) 1) common (> 10%) - weight gain, oily skin, acne, hirsutism, deepening of voice, amenorrhea, breakthrough bleeding, irregular menses, breast shrinkage 2) less common (1-10%) - edema, virilization, weakness, decreased estrogen 3) uncommon (< 1%) - photosensitivity, vaginitis (monilial & atrophic), testicular atrophy, enlargement of clitoris, bleeding gums, carpal tunnel syndrome, cholestatic jaundice, benign intracranial hypertension, pancreatitis 4) other - headache Drug interactions: - inhibits cyt P450 3A4 a) may increase levels of drugs metabolized by cyt P450 3A4 b) increased anticoagulant effect of warfarin Laboratory: - danazol in urine Mechanism of action: androgen

Interactions

drug adverse effects of androgens

Related

cytochrome P450 3A4 (cytochrome P450 C3, nifedipine oxidase, P450-PCN1, NF-25, CYP3A4)

General

androgen or anabolic steroid

Properties

MISC-INFO: elimination route LIVER pregnancy-category X safety in lactation -

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 403
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Deprecated Reference
  5. Department of Veterans Affairs, VA National Formulary